The Oncosearch | Oncotarget

Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma Research Paper

Charles R. Schutt, Hua Sun, Jaya Sarin Pradhan, Yvonne Saenger, Jessica Ley, Douglas Adkins, Matthew Ingham, Li Ding, Brian A. Van Tine

Published Feb 21, 2021 · Vol. 12, No. 6 · pp. 534-548

Keywords: head and neck squamous cell carcinoma, neoantigens, mutational evolution, tumor relapse, immune cell infiltration

Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models Research Paper

Helena Degroote, Sander Lefere, Astrid Vandierendonck, Bart Vanderborght, Tim Meese, Filip Van Nieuwerburgh, Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe, Lindsey Devisscher

Published Feb 20, 2021 · Vol. 12, No. 6 · pp. 562-577

Keywords: hepatocellular carcinoma, macrophage subsets, tumor microenvironment, tumor associated macrophages, inflammation

Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies Research Perspective

Ryan R. Kawalerski, Steven D. Leach, Luisa F. Escobar-Hoyos

Published Feb 12, 2021 · Vol. 12, No. 6 · pp. 525-533

Keywords: pancreatic cancer, RNA splicing, targeted therapy, KRAS, TP53

The role of immune surveillance in malignant transformation of benign salivary gland tumors Research Perspective

Maximilian Linxweiler, Jingming Wang, Luc G.T. Morris

Published Feb 10, 2021 · Vol. 12, No. 7 · pp. 592-595

Keywords: salivary tumor, salivary cancer, pleomorphic adenoma, immune surveillance

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

Leonardo G. da Fonseca, Carla Fuster-Anglada, Cristina Carrera, Cristina Millán, Esther Samper, Victor Sapena, Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, Cassia Leal, Alejandro Forner, Jordi Bruix, Maria Reig, Loreto Boix, Alba Díaz

Published Feb 5, 2021 · Vol. 12, No. 5 · pp. 440-449

Keywords: hepatocellular carcinoma, tyrosine kinase inhibitors, treatment adverse events, skin lesions, molecular profiling

High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma Research Paper

Eric Russ, Krithika Bhuvaneshwar, Guisong Wang, Benjamin Jin, Michele M. Gage, Subha Madhavan, Yuriy Gusev, Geeta Upadhyay

Published Jan 26, 2021 · Vol. 12, No. 3 · pp. 145-159

Keywords: LY6 genes, pancreatic cancer, immune cells, survival outcome

Tumor mutational burden as a predictor of immunotherapy response in breast cancer Research Perspective

Tess A. O’Meara, Sara M. Tolaney

Published Jan 23, 2021 · Vol. 12, No. 5 · pp. 394-400

Keywords: breast cancer, immunotherapy, tumor mutational burden

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva, Jose Manuel Mas

Published Jan 22, 2021 · Vol. 12, No. 4 · pp. 316-332

Keywords: ALK inhibitor, brigatinib, alectinib, mathematical model, systems biology

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

Rolando Pérez-Lorenzo, Stephanie O. Erjavec, Angela M. Christiano, Raphael Clynes

Published Jan 6, 2021 · Vol. 12, No. 2 · pp. 66-80

Keywords: anti-tumor antibodies, targeted therapy, immunotherapy, combination therapies, melanoma

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors Editorial

Erika J. Crosby, H. Kim Lyerly, Zachary C. Hartman

Published Dec 26, 2020 · Vol. 12, No. 1 · pp. 1-3

Keywords: breast cancer, tumor immunology animal models, T cell exhaustion, immune responses to cancer, tumor antigens/neoantigens

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation Case Report

Karam Khaddour, Joshua Dowling, Jiayi Huang, Martha Council, David Chen, Lynn Cornelius, Tanner Johanns, Sonika Dahiya, George Ansstas

Published Dec 13, 2020 · Vol. 11, No. 52 · pp. 4836-4844

Keywords: metastatic melanoma, immune checkpoint inhibitor, temozolomide, acquired resistance, beta-2 microglobulin

Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agent in vivo and retards B16-F10 melanoma growth in a preclinical model Research Paper

Adilson Kleber Ferreira, Brunella Cristofaro, Milene Cristina Menezes, Ana Karina de Oliveira, Alexandre Keiji Tashima, Robson Lopes de Melo, Cristiane Castilho Fernandes Silva, Miryam Guillermina Palomino Rodriguez, Daniela Cajado de Oliveira Souza Carvalho, Ricardo Alexandre de Azevedo, Paulo Luiz de Sá Junior, Lisley Inata Mambelli, Fernanda Vieira Portaro, Luc Pardanaud, Anne Eichmann, Osvaldo Augusto Sant’Anna, Mxarcella Faria

Published Nov 30, 2020 · Vol. 11, No. 51 · pp. 4770-4787

Keywords: alphastatin-C, angiogenesis, peptides, melanoma, angiostatic

Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas Research Perspective

Syed M. Faisal, Flor M. Mendez, Fernando Nunez, Maria G. Castro, Pedro R. Lowenstein

Published Nov 27, 2020 · Vol. 11, No. 50 · pp. 4607-4612

Keywords: immunotherapy, gene therapy, thymidine kinase, Flt3L, DIPG

High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages Research Paper

Jackie Bader, Meredith Carson, Reilly Enos, Kandy Velazquez, Alexander Sougiannis, Udai Singh, William Becker, Mitzi Nagarkatti, Daping Fan, Angela Murphy

Published Nov 24, 2020 · Vol. 11, No. 49 · pp. 4554-4569

Keywords: colorectal cancer, obesity, metabolism, macrophage, inflammation

Predictors of immunotherapy benefit in Merkel cell carcinoma Research Paper

Alec J. Kacew, Harita Dharaneeswaran, Gabriel J. Starrett, Manisha Thakuria, Nicole R. LeBoeuf, Ann W. Silk, James A. DeCaprio, Glenn J. Hanna

Published Nov 17, 2020 · Vol. 11, No. 47 · pp. 4401-4410

Keywords: cancer, genomics, immunotherapy, Merkel cell carcinoma, precision medicine

Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer Research Paper

Erika Heninger, Nan Sethakorn, David Kosoff, Peiman Hematti, Morgan D. Kuczler, Kenneth J. Pienta, Joshua M. Lang

Published Nov 10, 2020 · Vol. 11, No. 46 · pp. 4253-4265

Keywords: prostate cancer, bone marrow, tumor microenvironment, immune profiling, immune landscape

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020 · Vol. 11, No. 46 · pp. 4201-4223

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Lanlan Zhou, Kelsey Huntington, Shengliang Zhang, Lindsey Carlsen, Eui-Young So, Cassandra Parker, Ilyas Sahin, Howard Safran, Suchitra Kamle, Chang-Min Lee, Chun Geun Lee, Jack A. Elias, Kerry S. Campbell, Mandar T. Naik, Walter J. Atwood, Emile Youssef, Jonathan A. Pachter, Arunasalam Navaraj, Attila A. Seyhan, Olin Liang, Wafik S. El-Deiry

Published Oct 28, 2020

Keywords: ACE2, TMPRSS2, SARS-CoV-2, COVID-19, pseudovirus

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Niraj Lodhi, Moe Tun, Poonam Nagpal, Arati A. Inamdar, Nehad M. Ayoub, Noor Siyam, Lucia Oton-Gonzalez, Angela Gerona, Dainelle Morris, Rana Sandhu, Kwangsun Stephen Suh

Published Oct 20, 2020 · Vol. 11, No. 44 · pp. 4045-4073

Keywords: DLBCL, diagnosis, R-CHOP, precision medicine, prognosis

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper

Robert A. Kazmierczak, Bakul Dhagat-Mehta, Elke Gulden, Li Lee, Lixin Ma, Clintin P. Davis-Stober, Austen A. Barnett, Chiswili Yves Chabu

Published Oct 4, 2020 · Vol. 11, No. 44 · pp. 3943-3958

Keywords: salmonella, cancer targeting, prostate cancer, immunotherapy, TRAMP

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma Research Paper

Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models Research Paper

Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies Research Perspective

The role of immune surveillance in malignant transformation of benign salivary gland tumors Research Perspective

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma Research Paper

Tumor mutational burden as a predictor of immunotherapy response in breast cancer Research Perspective

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors Editorial

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation Case Report

Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agent in vivo and retards B16-F10 melanoma growth in a preclinical model Research Paper

Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas Research Perspective

High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages Research Paper

Predictors of immunotherapy benefit in Merkel cell carcinoma Research Paper

Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma Research Paper

Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models Research Paper

Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies Research Perspective

The role of immune surveillance in malignant transformation of benign salivary gland tumors Research Perspective

Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity Research Paper

High mRNA expression of LY6 gene family is associated with overall survival outcome in pancreatic ductal adenocarcinoma Research Paper

Tumor mutational burden as a predictor of immunotherapy response in breast cancer Research Perspective

Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach Research Paper

Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma Research Paper

Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors Editorial

Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation Case Report

Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agent in vivo and retards B16-F10 melanoma growth in a preclinical model Research Paper

Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas Research Perspective

High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages Research Paper

Predictors of immunotherapy benefit in Merkel cell carcinoma Research Paper

Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection Priority Research Paper

Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine Review

Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model Research Paper